FLORHAM PARK, NJ--(Marketwired - Oct 17, 2016) - Hisamitsu America, a division of Hisamitsu Pharmaceutical Co., Inc., and the manufacturers of the Salonpas® Pain Relief Patch which is the one and only OTC pain patch that is FDA approved and clinically proven, maintains their commitment to providing industry leading, topical analgesic solutions with the launch of the new Salonpas® Lidocaine 4% Pain Relieving Gel-Patch. The patch features the maximum strength lidocaine available without a prescription, using a proprietary hydro-gel technology to sooth aggravated nerves.
"We developed the Salonpas® Lidocaine 4% Pain Relieving Gel-Patch to be as close as possible to the 5% prescription Lidocaine patches. Our Lidocaine is delivered using our proprietary coating technology which ensures precise and even delivery of medicine at the site of pain," said John Incledon, President & CEO, Hisamitsu America. "These unscented patches provide numbing relief to desensitize aggravated nerves for hours of pain relief."
"I tried the Salonpas® Lidocaine 4% Pain Relieving Gel-Patch after a rigorous paddle-boarding session to address my 'tennis elbow' and found that the patch worked as effectively as a much stronger prescription patch," said award-winning journalist Dr. Bob Arnot, M.D., internal medicine who served as chief medical and foreign correspondent for NBC and CBS.
The new Salonpas® Lidocaine 4% Pain Relieving Gel-Patch (MSRP: $11.99) is available at leading retailers nationwide. The active ingredient for this convenient and versatile patch is lidocaine (4%) which provides temporary relief of minor aches and pains.
Salonpas® is the leading OTC pain relieving patch brand available in the United States. The company manufactures their own product ensuring strict adherence to the highest quality standards. Salonpas® sells 13 patches every second with over 1 million sold daily in the United States.
About Hisamitsu America:
Hisamitsu America is the US division of Hisamitsu Pharmaceutical Co., Inc., founded in 1847, which has specialized in transdermal drug delivery system technology since the introduction of its Salonpas line of patches in 1934. The SALONPAS® product line, which gained early acceptance in Japan and now sells in over 50 countries, has pioneered the development of transdermal patches to relieve everyday aches and pains. Today, the Salonpas® Pain Relief Patch is the first and only FDA-approved OTC pain patch. For more information, visit www.salonpas.us.
Contact Information:
Media Contact:
Nancy Tamosaitis
Vorticom, Inc.
212.532.2208
